Bosh sahifaSGIOY • OTCMKTS
add
Shionogi 2 ADR Representing 1 Ord Shs
Yopilish kursi
6,93 $
Kunlik diapazon
6,94 $ - 7,03 $
Yillik diapazon
6,22 $ - 9,11 $
Bozor kapitalizatsiyasi
1,87 trln JPY
Oʻrtacha hajm
233,49 ming
Yangiliklarda
4507
0,094%
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(JPY) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 116,38 mlrd | -4,00% |
Joriy xarajat | 52,93 mlrd | -3,66% |
Sof foyda | 52,50 mlrd | 9,30% |
Sof foyda marjasi | 45,11 | 13,86% |
Har bir ulushga tushum | — | — |
EBITDA | 53,13 mlrd | -5,14% |
Amaldagi soliq stavkasi | 8,28% | — |
Balans
Jami aktivlari
Jami passivlari
(JPY) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 303,40 mlrd | 20,22% |
Jami aktivlari | 1,46 trln | 3,34% |
Jami passivlari | 145,93 mlrd | -18,09% |
Umumiy kapital | 1,31 trln | — |
Tarqatilgan aksiyalar | 850,69 mln | — |
Narxi/balansdagi bahosi | 0,00 | — |
Aktivlardan daromad | 8,22% | — |
Kapitaldan daromad | 9,10% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(JPY) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | 52,50 mlrd | 9,30% |
Operatsiyalardan naqd pul | 45,30 mlrd | 220,14% |
Sarmoyadan naqd pul | -17,63 mlrd | 47,30% |
Moliyadan naqd pul | -1,11 mlrd | 94,50% |
Naqd pulning sof oʻzgarishi | 21,45 mlrd | 158,43% |
Boʻsh pul | 8,02 mlrd | 135,46% |
Haqida
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Tashkil etilgan
1878
Bosh ofis
Sayt
Xodimlar soni
4 959